InSite Vision has secured the new patent for its DuraSite 2 next-generation enhanced drug delivery system from the United States Patent and Trademark Office (USPTO).
DuraSite 2's ability to significantly improve drug retention and penetration into the tissues of the eye may help it serve as a broad platform for developing topically delivered ocular drugs.
The patent number 8,501,800 will protect the utility and composition for both the delivery system and the drugs that are formulated with DuraSite 2 till 2029.
InSite Vision CEO Timothy Ruane said, "We plan to utilize the DuraSite 2 platform in the development of all future InSite Vision pipeline products and seek partners via licensing agreements."
Results from a preclinical comparative study showed that the DuraSite 2 formulation has achieved more than 2x and 4x concentrations in the aqueous humor of the eye as compared to the DuraSite formulation or marketed drug, respectively.
The results also suggested that DuraSite 2's increased tissue penetration enable it to be used in the treatment of back-of-the-eye diseases with a topical eye drop when formulated with drugs that must currently be administered by injection.
InSite Vision recently presented this data at the Association for Research in Vision and Ophthalmology (ARVO) 2013 annual meeting.
The Journal of Ocular Pharmacology and Therapeutics accepted a detailed scientific paper entitled 'Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2" for publication on July 30, 2013.
